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Precis: Accurate prognostication is essential to the optimal management of laryngeal cancer, but 
suboptimal reliability and accuracy limit the integration of existing individualized prediction 
tools into routine clinical decision making. Further development of individualized prognostic 
calculators may improve risk prediction, treatment planning, and counselling for patients with 
laryngeal cancer. 
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Abstract 
Background: Accurate prognostication is essential to the optimal management of laryngeal 
cancer. Predictive models have been developed to calculate the risk of oncologic outcomes, but 
extensive external validation of accuracy and reliability is necessary prior to implementing them 
into clinical practice. 
Methods: Four published prognostic calculators that predict five-year overall survival for 
patients with laryngeal cancer were evaluated using patient information from a prospective 
epidemiology study cohort (n=246; median follow-up 60 months) with previously untreated 
stage I-IVb laryngeal squamous cell carcinoma.  
Results:  Different calculators can give substantially different predictions for individual patients. 
The observed 5-year overall survival was significantly higher than the averaged predicted 5-year 
overall survival of the four calculators (71.9% [95% CI 65%-78%] versus 47.7%). Statistical 
analyses demonstrated the calculators’ limited capacity to discriminate outcomes for risk-
stratified patients. The AUC ranged from 0.68 to 0.72. C-index values were similar for each of 
the four models (0.66 to 0.68). There was a lower than expected hazard of death for patients who 
received induction (bioselective) chemotherapy (HR 0.46 [0.24, 0.88] p=0.024) or primary 
surgical intervention (HR 0.43 [0.21, 0.90] p-value 0.024) compared to concurrent 
chemoradiation. 
Conclusions: Suboptimal reliability and accuracy limit the integration of existing individualized 
prediction tools into routine clinical decision making. The calculators predicted significantly 
worse-than-observed survival among patients treated with induction chemotherapy and primary 
surgery, suggesting a need for updated consideration of modern treatment modalities. Further 
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development of individualized prognostic calculators may improve risk prediction, treatment 
planning, and counselling for patients with laryngeal cancer. 
 
  
Page 5 of 47 Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 6
Introduction 
The multidisciplinary management of head and neck cancer (HNC) is critically 
dependent upon accurate risk stratification and prediction of clinical outcomes.
1
 Managing 
laryngeal cancer introduces additional challenges secondary to debilitating functional 
impairments that often accompany the primary disease and/or related therapeutic interventions.
2-5
 
Accepted standards for tumor staging and oncologic prognostication continue to be helpful in 
confronting these challenges and guiding decision making.
6, 7
 However, more sophisticated 
methods are mandatory in order to capitalize on discoveries related to tumor biology/genomics 
and patient factors and their ability to further individualize treatment selections that enhance 
survival and minimize morbidity.
8, 9
 Treatment decision making is particularly complex for 
laryngeal cancer due to the variety of treatment options available and differing short- and long-
term functional consequences that affect quality of life and survival. The management of 
laryngeal cancer has experienced substantial evolution, primarily driven by the implementation 
of chemotherapeutic modalities and novel organ preservation strategies.
3, 10-12
 This further 
emphasizes the need for modernized tools when calculating prognostic estimates. 
The heterogeneity of laryngeal cancer is one of the many factors that impose formidable 
challenges to the accurate prediction of individual survival.
13
 Survival is influenced by numerous 
variables, including multiple and diverse tumor specific (size, grade, genomics, biological 
features, and stage) and patient related (age, race, gender, immune status, smoking status and 
medical comorbidities) factors.
14
 The TNM (tumor–node–metastasis) staging system defined by 
the American Joint Committee on Cancer (AJCC) is the current prognostic standard for head and 
neck cancer and predicts survival with reasonable accuracy.
15
 Despite its trusted reputation and 
ubiquitous assimilation in clinical practice, TNM staging fails to incorporate many criteria that 
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demonstrate prognostic value, thereby limiting its ability to tailor risk predictions to an 
individual patient.
15
 Studies suggest that implementing additional tumor, patient and treatment 
characteristics into risk calculations can promote superior prognostic accuracy across a diverse 
range of oncologic subspecialties.
16-19
 
 The current trend in attitudes toward electronic health information suggests that online 
versions of these calculators would be readily implemented into medical decision making.
20- 24
 
As a means of regulating newly published risk predictors, the AJCC recently published sixteen 
inclusion and exclusion criteria that are required for endorsement of any probability or risk 
model.
25
 These benchmarks should help to ensure that performance metrics, compatibility, and 
clinical relevance are robust amidst the expansion of new prediction tools.
25
 
 Investigators have worked to address the dearth of individualized clinical decision tools 
currently available to interdisciplinary teams that manage head and neck squamous cell 
carcinoma (HNSCC) by developing prognostic calculators specific to head and neck cancers.
26-28
 
Risk calculators wield potential clinical value but have not yet been subjected to sufficient 
evaluation and validation to warrant their assimilation into routine practice. Moreover, many of 
these were generated with older data that may not be directly relevant to current patients. In 
order to assess clinical prognostic tools, analyses that compare the calculators’ predictions to 
each other and to modern observed outcomes are imperative.
29
 These validation studies are best 
performed on independent patient cohorts that encompass diverse geographic regions and patient 
demographics.
30, 31
 Our goal was to utilize an independent patient cohort to externally evaluate 
and validate published prognostic calculators designed for patients with laryngeal cancer. 
Materials and methods 
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The University of Michigan IRBMED evaluated and approved this study. All subjects 
provided written informed consent at enrollment in this prospective epidemiology study 
(typically at the time of diagnosis). 
Prognostic Calculators 
Prognostic clinical decision tools were identified via online search engines and expert 
input. Pubmed and Google Scholar were investigated for peer-reviewed publications using a 
combination of search terms representing disease (larynx, cancer), prognosis (i.e. survival, risk, 
prediction and outcome) and methodology (calculator, tool, model and nomogram). 
Multidisciplinary head and neck cancer specialists were also surveyed in order to probe for 
existing or emerging prognostic tools not identified in the online search.
16
  
 Potential calculator candidates were evaluated for eligibility. Inclusion criteria mandated 
that the calculator utilized clinical data to predict five-year overall survival for squamous cell 
carcinoma of the larynx. Four prognostic calculators were identified (MAASTRO, Lifemath, 
Leiden, and MyCancerJourney) and each model was reviewed for content and format.
26-28
 The 
calculators’ mathematical formulas were acquired from the original publication, supplementary 
online materials, or computational derivation. Notably, MyCancerJourney does not have an 
associated peer-reviewed publication. 
 Table 1 summarizes each calculator and includes the period, sample size, and other 
characteristics that describe the original study cohorts. Each calculator functions according to an 
equation constructed to represent the relationship between tumor characteristics, patient 
demographics, employed treatment modalities and observed survival outcomes. The calculators 
considered a distinct set of variables in their prognostic equation and assigned differing 
quantities of statistical weight to these variables (Table 2 and Supplementary Tables 1 - 7, 
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available online). The calculators were modeled from patient data contained in the Surveillance, 
Epidemiology, and End Results (SEER) registry, regional study cohorts, or a combination of two 
patient populations. The four study cohorts included patients treated with curative intent between 
1973 and 2009 
26-28
. 
Patients 
The analysis data set was derived from a single-institution prospectively maintained head 
and neck cancer epidemiologic study.
32-35
  A total of 246 patients with biopsy-proven, previously 
untreated, AJCC stage I-IVb squamous cell carcinoma of the larynx diagnosed and treated with 
curative intent at the University of Michigan Health System between 2003 and 2014 were 
included. Table 2 provides additional summary demographics for the cohort. Patients were 
evaluated by our multidisciplinary team and discussed at our Tumor Board where treatment 
recommendations were formulated.  Patients with Stage I or II disease were generally treated 
with single modality surgery (33 [35.1%]), radiotherapy alone (50 [53.2%]), or concurrent 
chemoradiotherapy for deeply invasive T2 lesions (11 [11.7%]). Patients with Stage III or IV 
disease received either primary surgery (32 [20.1%]), a single cycle of induction chemotherapy 
(bioselective) followed by either combined chemoradiation for greater than 50% tumor response 
or total laryngectomy for less than 50% tumor response (70 [46.1%]), or definitive 
chemoradiation (50 [32.9%]). Median follow-up was 60 months. Tumor, patient and treatment 
specific variables were exported from the database and confirmed via chart abstraction.  
The calculators were designed for utility prior to oncologic treatment. Consequently, 
pretreatment clinical information was used to populate the relevant variables. Pathological 
information was only used as a substitute when clinical information was not available. Missing 
variables were populated using established algorithms described in the supplementary online 
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materials. Exclusion criteria included carcinoma in-situ, distant metastasis at the time of 
diagnosis and synchronous primary tumors not including basal or squamous cell carcinoma of 
the skin.  
Statistical Analysis 
Each calculator was used to individually predict five-year overall survival for 246 
patients in our independent cohort. The arithmetic average of the predictions from the four 
calculators was tested as a distinct (fifth) calculator, referred to as the “mean” in subsequent 
analyses. The agreement between these predictions was compared using scatterplots, Spearman’s 
correlation coefficients and the proportion of five-year overall survival predictions that differed 
by less than 0.10 between separate calculators. The calibration of each calculator was assessed 
using Kaplan-Meier plots that stratified patients into equal-sized quintiles according to 
calculator-predicted risk. The average predicted risk for each quintile was compared to the 
estimated five-year survival for that quintile in a calibration plot. The discriminatory ability of 
each calculator was assessed using both the area under the ROC curve for the binary outcome of 
survival at five years
36
 and the C-index. Both the C-index and the five year AUC measure the 
concordance between the predicted risk and the survival outcome and are frequently reported in 
the literature.  
To assess which factors may be responsible for discrepancies between the predicted 
outcomes and observed survival, a separate Cox model was fit for each possible factor and 
adjusted for the predicted risk as measured by the mean prediction. All tests for statistical 
significance utilized 95% confidence intervals and were two-sided. For treatment factors, a 
calibration plot was used to elucidate which treatment modalities were not well calibrated with 
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the predicted risk. The method used to construct the calibration plot is described in the 
supplementary online materials. 
Results 
The patient cohort represents the typical distribution and epidemiology of patients with 
laryngeal cancer.  Most patients were Caucasian, current/former smokers, and male with no or 
mild medical comorbidities. Slightly less than half had a glottic subsite whereas the majority 
originated in the supraglottic larynx.  
Observed 5-year overall survival was 71.9% [95% CI of 65% to 78%] whereas each of 
the calculators predicted significantly worse outcomes and contributed to a mean predicted 5-
year overall survival of 47.7%. Figure 1 describes each calculator’s predicted 5-year survival for 
our patient population. Visual assessment of the estimates suggests that MAASTRO and 
MyCancerJourney have a tendency to predict worse outcomes; both have more predictions 
clustered at lower values than the other calculators. MAASTRO showed the greatest discrepancy 
in its prognostication for patients with high-risk disease. MyCancerJourney has more variation in 
its predictions. Comparisons of MyCancerJourney and MAASTRO against the remaining two 
calculators demonstrated less agreement and were characterized by lower correlation 
coefficients.  
The Leiden and Lifemath calculators demonstrated the closest correlation coefficient 
(rho=0.816) and the weakest association occurred between Lifemath and MyCancerJourney 
(rho=0.644). Supplementary Table 8, available online, reports the percentage of patients for 
which a selected pair of calculators predicted 5-year overall survival within 0.10. For example, if 
one calculator predicted a 50% 5-year overall survival for a given patient, the paired calculator 
was considered to be in consensus if it predicted between 40 and 60% 5-year overall survival for 
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the same patient. Prognostic consensus between calculators was found to be variable and survival 
estimates typically agreed within 0.10 for less than 50% of the cohort.  
Figure 2a displays Kaplan-Meier survival plots that used calculator predictions to risk-
stratify the patients into equal-portioned quintiles. The four calculators were reasonably effective 
in discriminating between these risk quintiles but Lifemath and Leiden were less adroit in 
stratifying low and high risk patients whereas MyCancerJourney and MAASTRO were less able 
to discriminate mid-tiered risk. The mean of the calculators more accurately stratified risk for 
each of the quintiles. 
Figure 2b displays ROC curves and their accompanying AUC and C-index scores for 
each of the four calculators. These values provide informative measures of prognostic 
discrimination. The AUC values were similar for each of the four models and fell into a range 
from 0.68 (Leiden) to 0.72 (MAASTRO and Mean). The C-index values ranged from 0.66 
(MAASTRO, Leiden and MyCancerJourney) to 0.68 (Lifemath and Mean).  
Calibration studies are summarized in Figure 3a and demonstrate lower survival 
estimates in relation to observed outcomes for each risk-stratified quintile. MAASTRO was 
especially pessimistic for high risk patients; Lifemath was well calibrated to observed outcomes 
for patients with mid-tiered risk. 
Cox modeling identified male gender (HR 2.03 [1.00, 4.11] p-value 0.031) and initial 
planned treatment as additional factors that were found to add predictive value even after 
adjusting for the predicted risk from the calculators. Laryngeal subsite (glottis vs. supraglottic) 
was not significantly related to survival after adjusting for calculator predictions (eTable 9). 
Figure 3b demonstrates that there was a lower than expected hazard of death for those patients 
in the cohort who underwent induction (bioselective) chemotherapy (HR 0.46 [0.24, 0.88] p-
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value 0.024) or primary surgical intervention (HR 0.43 [0.21, 0.90] p-value 0.024) compared to 
primary chemoradiation. Adjusted hazard ratios for all other factors are shown in 
Supplementary Table 9, available online. 
Discussion: 
Available prognostic calculators generated variable predictions with inconsistent 
accuracy when compared to observed outcomes in an external prospectively maintained cohort 
of patients with laryngeal cancer. The four calculators were designed with varying degrees of 
similarity but substantial disparity in performance was evident. We have reported both the 
discriminatory ability and the calibration properties of the calculators, these can be thought of as 
measures of the accuracy of the relative and absolute predictions respectively.  Relative 
predictions are whether the patients can be correctly ranked according to risk, and absolute 
predictions are whether the predicted probabilities of survival are correct. Both are important, 
and neither is good for any of the four calculators.  
Differences in patient cohorts, prognostic variables, statistical modeling and inherent 
calculator limitations contributed to this variation and highlight many of the challenges 
associated with oncologic prognostication. LifeMath and MyCancerJourney both utilized the 
SEER population as their study cohort but exhibited the weakest association in risk prediction. 
This observation emphasizes the importance of incorporating and weighing prognostic variables 
accurately.
37
 Comorbidity status has proven to be useful in predicting outcomes but was only 
integrated into the Leiden and MyCancerJourney calculators, providing further explanation for 
observed differences in calculator performance.
38 
The AJCC established guidelines in 2016 that 
work to synchronize the development of future prognostic calculators, but meaningful 
discrepancies in the perceived importance of prognostic variables will likely persist.
25
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The MAASTRO calculator was developed in the Netherlands using a study cohort of 994 
patients with laryngeal cancer from 1977 to 2008.
27
 This calculator was designed for patients 
who only received radiation therapy as their primary treatment modality and exclusion criteria 
included carcinoma in-situ, distant metastases, and chemotherapy. MAASTRO’s internal 
validation demonstrated an AUC of 0.73 whereas traditional TNM staging demonstrated an AUC 
of 0.62 for the study cohort.
27
 Previous external validations yielded AUC values of 0.68, 0.74, 
0.76, and 0.71. When compared to survival predictions for our entire external cohort, predictions 
for the 55 subjects who exclusively received radiation demonstrated similar calibration, better 
correlation to predictions from the other calculators, and substantially improved AUC and C-
index values (Supplementary Table 10 and Figures 1, 2 and 3, available online). Our study 
produced the first non-European external validation with an AUC of 0.72 when applied to all 246 
patients and an AUC of 0.81 when applied to just those 55 patients who received radiation only. 
This calculator’s pessimistic tendency could be explained by the evolving role of multimodality 
therapy, although the absolute incremental overall survival benefit of chemotherapy over 
radiation alone in laryngeal cancer is fairly modest (5%) outside of bioselection
39
, The calculator  
also has a noticeable unfavorable hazard ratio for male gender and low hemoglobin count, 
however many patients in our cohort were anemic but had better-than-predicted outcomes. In 
summary, the calculator’s performance was fair considering the fundamental differences in the 
study cohort from which it was developed. 
The LifeMath calculator was developed using 50,145 American patients with all sites of 
head and neck cancer in the SEER database from 1980 to 2009.
26
 Internal validation and external 
validation on 1,362 patients from the Massachusetts General Hospital were performed using an 
incomparable correlation metric. This study provides an external validation with a C-index of 
Page 14 of 47Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 15
0.68 and AUC of 0.71. The accuracy of this calculator may have been limited by its neglect of 
comorbidity status, a variable that is not available in the SEER database.  
The Leiden calculator was developed using a study cohort of 1371 Dutch patients with 
several different sites of head and neck cancer from 1981 to 1998.
28
 Internal validation 
demonstrated a C-index of 0.73 whereas an external validation on 598 patients from the Siteman 
Cancer Center yielded a C-index of 0.69. This study provides an additional external validation 
with a C-index of 0.66. The model likely produced pessimistic survival estimates due to 
evolution and refinement of treatment over the past four decades. 
MyCancerJourney used SEER data from 1973 to 1996 and Barnes-Jewish Hospital data 
from 1995 to 2001 to construct its model but did not have a publication to accompany its online 
calculator. The calculator performed with a C-index of 0.66 and AUC of 0.70 in this study. 
MyCancerJourney employed a novel comorbidity metric to characterize patients. The majority of 
variability in outcome predictions could be explained by the grouping of patients according to 
treatment modality and other parameters that resulted in substantial prognostic fluctuation. 
Each of the calculators was designed using a training dataset that included patients from 
over 35 years ago. Consequently, many of the patients in the study cohort were not treated 
according to modern strategies. Reliance on older patient data is likely to have contributed to the 
accumulative tendency to estimate worse-than-observed survival in the study cohort and 
underscores the importance of ensuring reliability and accuracy before adopting these into 
clinical practice.  
In contrast to a previous study of currently available oral cavity cancer calculators, the 
laryngeal cancer patients in our cohort demonstrated consistently better survival when compared 
to the calculators’ predicted outcomes.
30
 This observation reinforces the hypothesis that 
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individualized treatment paradigms for laryngeal cancer need to be considered when predicting 
survival. Whether this represents differences among the patients themselves or the individualized 
treatment approaches utilized remains speculative. However, induction chemotherapy 
(bioselective) for subsequent treatment selection and/or primary surgical intervention were both 
associated with survival benefits that were greater than expected following adjustments for 
calculator-estimated survival. Individualized treatment paradigms that integrate neoadjuvant 
bioselection are associated with a significant survival benefit and may account for the superior 
outcomes observed.
35
 These findings reinforce the need for updated survival calculators and 
provide further evidence that oncologic interventions and institution-specific care are 
independent variables that affect the prognosis of patients with laryngeal cancer.   
The absence of laryngeal cancer clinical practice guidelines that clearly specify 
preferred treatment modality may be contributing to disparities in calculator performance. 
Established practice guidelines help to optimize patient outcomes and standardize the value of 
care.
40-42
 However, emerging evidence suggests that adherence to current guidelines established 
by the American Head and Neck Society (AHNS) and National Comprehensive Cancer 
Network (NCCN) does not significantly improve outcomes.
43
 Therapeutic regimens are 
complicated by the range of available treatment modalities and the need to individualize these 
based upon patient, tumor and institutional factors, making population-level recommendations 
challenging.
44
  
There is a growing impetus for evaluating value of cancer care. Judging value involves 
the balanced consideration of quality and outcome delivered, and remains especially difficult to 
measure in oncology due to its multidisciplinary nature, need for prolonged follow-up, and 
consideration of post-treatment function as well as survival.
45
 In order to address these 
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challenges, prognostic calculators could be modeled from patient cohorts treated in accordance 
to optimized quality metrics. Once appropriately accurate, precise and calibrated, such 
calculators could help to establish standardized expected outcomes for individually risk-stratified 
patients. Comparing an institution’s outcomes to calculator predictions on an individualized and 
risk-stratified basis may serve as an effective method for evaluating and comparing relative 
quality and value.
45, 46
  
There are inherent limitations to this study, chiefly involving the single-institutional data, 
which may not reflect practice patterns or outcomes in other populations. The patients in our 
cohort were also treated by an experienced multidisciplinary team and had comprehensive follow 
up allowing appropriate salvage treatment for recurrence when necessary. Additional limitations 
may be linked to the improved outcomes generally associated with treatment in academic 
centers.
35, 40, 42, 47-49
 The accuracy of the SEER data, as well as the calculators relying on it, may 
be confounded if incurable patients treated for palliation were included or other inaccuracies in 
treatment details were present. Missing variables were an additional source of error in this 
evaluation. However, derived values (see missing variable methods in the supplement) for 
hemoglobin, radiation dosage and tumor diameter rarely led to substantial differences in survival 
predictions, helping to mitigate this concern. The calculators do not consider the role of human 
papillomavirus (HPV); the incidence and prognostic impact of HPV in laryngeal cancer is 
considerably lower than oropharyngeal cancer
50
. 
 There is a need for more accurate prognostic calculators that predict individualized 
outcomes for patients with laryngeal cancer. Currently available prognostic calculators varied in 
their ability to consistently and accurately predict survival in an external cohort of patients with 
laryngeal cancer. Suboptimal reliability and accuracy limit the potential integration of existing 
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individualized prediction tools into routine clinical practice. The calculators estimated 
significantly worse-than-observed survival among patients treated with induction bioselective 
chemotherapy and primary surgery, suggesting that modern treatment modalities must be better 
integrated into revised prediction tools. Deficiencies in calculator performance may be further 
explained by institutional variation in oncologic outcomes. Potential avenues to improve 
performance of calculators include utilizing contemporary patient cohorts, integrating 
biomarkers and harnessing the promise of the genomic frontier as these data emerge. The use of 
statistical and machine learning approaches when datasets are large is another intriguing 
possibility to create mechanisms that can more nimbly respond to exponentially complex and 
evolving data 
51
. 
These data raise questions about the inherent value of oncologic nomograms. We contend 
that they are useful for patients to estimate individualized prognosis, and perhaps for comparing 
results across different cohorts. Predictive models that guide treatment selection might be of 
higher value and could see increasing demand as the arsenal of available therapies continues to 
proliferate and individualize. Improved individualized calculators may help to assign value of 
oncologic care and will be critical in refining the ability of multidisciplinary teams to predict 
risk, plan shared treatment-related decision making, and counsel patients effectively.  
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Figure Legends: 
Figure 1: Scatterplots Comparing Calculator Predictions 
 
 
Legend: The histograms on the diagonal show the distribution of predicted 5-year survival from 
each calculator for the 246 University of Michigan patients. The scatterplots below the diagonal 
show individual predictions of 5-year overall survival from pairs of calculators when applied to 
the University of Michigan patients. Points close to the 45 degree line are from patients with 
similar predictions from the two calculators. Correlation coefficients from the scatterplots are 
shown above the diagonal. 
 
Figure 2: Comparison of Calculator Predictions to Observed Outcomes 
 
 
Legend: Figure 2a shows the Kaplan-Meier overall survival estimates stratified by quintile of 
predicted 5-year survival for each calculator. Figure 2b shows the ROC curves of sensitivity and 
specificity of each calculators predicted 5-year survival compared to the observed 5-year 
survival.   
 
Figure 3: Calibration of Calculator Predictions to Observed Outcomes 
 
 
Legend: Figure 3a shows the calibration of each calculator. Each point represents a set of 
patients with similar predicted probability of 5-year survival (grouped by quintiles). The 
horizontal axes represent the average predicted probability of the group, the vertical axis show 
the observed 5-year survival for the group obtained from Kaplan-Meier plots. A well calibrated 
calculator would have points near the diagonal line. Figure 3b shows the calibration curves 
stratified by initial treatment plan. Each point represents a small group of patients who have 
similar predicted 5-year survival and the same initial treatment.   
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Table 1: Summary of Calculators 
Calculator 
Cancers 
in 
training 
dataset 
Training 
dataset 
Validation dataset Model Type Model Details 
MAASTRO  
(Egelmeer et 
al 2011)  
Larynx 
994 patients 
with 
laryngeal 
carcinoma 
treated with 
RT from 
1977-2008 
(89.9% N0) 
 
Leuven; 109 patients 
treated with RT from 
2000-2006 (75.2% N0). 
VU Amsterdam; 178 
patients treated with 
RT from 2001-2007 
(92.7% N0). 
NKI/AML Amsterdam; 
205 patients treated 
with RT from 2000-
2008 (89.8% N0). 
Manchester; 403 
patients treated with 
RT from 1998-2005 
(98.8% N0) 
 
Cox 
Regression 
Main effects 
only. 
LifeMath 
(Emerick et 
al 2013) 
HN HN patients 
in  SEER up 
to 2009 
Massachusetts General 
Hospital 1362 patients 
Statistical-
mechanistic 
model of 
cancer 
metastasis 
involving 
separate tumor 
and node 
contributions. 
Complicated 
formulas with 
many parameters 
and interactions.  
 
Leiden  
(Datema et 
al 2013) 
HN 1371 
patients 
(638 with 
laryngeal 
cancer) at 
Leiden 
University 
Medical 
Centre 
1981-1999 
598 pts Barnes-Jewish 
Hospital between 1995- 
2000 
Cox regression Main effects 
only. 
MyCancer 
Journey *   
All 
cancers 
SEER 1973-
1996 and 
11,791 
Barnes-
Jewish 
Hospital 
patients  
1995-2001  
No validation data. Cox regression Main effects and 
many 
interactions. 
 
*Calculator available online at https://staging.mycancerjourney.com/myinsights/survival-curves. 
Page 27 of 47 Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 28
Table 2: Patient Characteristics (N=246) 
 N  (%)*
 
or Mean (SD) 
Missing, N  (%) Calculators using 
Characteristic 
Demographics    
Age at Diagnosis 60.0  (10.2) 0  (0) All four 
Gender 
  Female 
  Male 
 
56  (22.7) 
190  (77.2) 
 
0  (0) 
 
All four 
Race 
  Black 
  Other 
  White 
 
9  (3.6) 
9  (3.6) 
228 (92.6) 
 
0  (0) 
 
LifeMath, MyCJ 
Smoking Status 
  Current (in past 12 mos) 
  Former (>12 mos) 
  Never 
 
166  (67.4) 
61  (24.7) 
18  (7.3) 
 
1  (0.4) 
 
None 
ACE Comorbidities 
  None 
  Mild 
  Moderate 
  Severe 
 
49  (19.9) 
112  (45.5) 
60  (24.3) 
25  (10.1) 
 
0  (0) 
 
MyCJ 
ACE Comorbidities (w/o Prior Tumors) 
  None 
  Mild 
  Moderate 
  Severe 
 
53  (21.5) 
118  (47.6) 
58  (23.5) 
17  (6.9) 
 
 
0  (0) 
 
Leiden 
Tumor Information    
Primary Site 
  Glottic 
  Supraglottic 
  Subglottic 
 
115  (46.7) 
131  (53.2) 
0 (0) 
 
0  (0) 
 
Leiden, MAASTRO 
AJCC Overall Stage 
  I 
  II 
  III 
  IV 
 
60  (24.3) 
34  (13.8) 
53  (21.5) 
99  (40.2) 
 
0  (0) 
 
 
None 
SEER Stage 
  Localized 
  Regional 
  Distant 
 
103 (41.7) 
92 (37.2) 
51 (20.6) 
 
0  (0) 
 
MyCJ 
T Stage  
  1 
  2 
  3 
  4 
 
64  (25.9) 
52  (21.1) 
71  (28.8) 
59  (23.9) 
 
0  (0) 
 
Leiden (MAASTRO after 
transformation) 
N Stage  
  0 
  1 
  1b 
  2 
  2a 
  2b 
  2c 
  3 
 
156  (63.4) 
26  (10.5) 
1  (0.4) 
1  (0.4) 
2  (0.8) 
24  (9.7) 
33  (13.4) 
3  (1.2) 
 
0  (0) 
 
LifeMath 
(transformation used for 
Leiden,  MAASTRO) 
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Number of Positive Nodes 
  0 
  1 
  2 
  3 
  4 
  5+ 
 
157 (63.8) 
33  (13.4) 
24 (9.7) 
19  (7.7) 
10  (4.0) 
3  (1.2) 
 
0  (0) 
 
LifeMath 
Tumor Diameter 
  Mean 
  <1.5cm 
  1.5-2.5cm 
  2.5-3.5cm 
  >3.5cm+ 
 
2.6  (1.49) 
31  (12.6) 
34  (13.8) 
43  (17.4) 
35  (14.2) 
 
103  (41.8) 
 
LifeMath 
Grade 
  1  (well) 
  2  (moderate) 
  3  (poor) 
  4  (undifferentiated) 
  Unknown 
 
38  (15.4) 
117  (47.5) 
40  (16.2) 
1  (0.4) 
50  (20.3) 
 
0  (0) 
(Unknown category) 
 
MyCJ 
Extracapsular Spread 
  Irrelevant (No Nodes) 
  No 
  Yes 
  Unknown 
 
157  (63.5) 
18  (7.3) 
43  (17.4) 
28  (11.3) 
 
0  (0) 
(Unknown category) 
 
LifeMath 
Margins 
  Negative 
  Positive 
 
78  (31.7) 
5  (2.0) 
 
163  (66.2) 
 
 
None 
Hemoglobin (g/dl) 13.8  (1.69) 45  (18.2) MAASTRO 
    
Treatment Information    
Initial Treatment Plan  
  Induction Chemo 
  No Induction Chemo 
    Surgery  
    Chemoradiation  
    Radiation Only 
 
70  (28.4) 
 
65  (26.4) 
56  (22.7) 
55  (22.3) 
 
0  (0) 
 
None 
Surgery (within 4 months) † 
  No 
  Yes 
 
166  (67.4) 
80  (32.5) 
 
0  (0) 
 
MyCJ 
Chemotherapy (within 4 months) † 
  No 
  Yes 
 
107  (43.4) 
139  (56.5) 
 
0  (0) 
 
 
MyCJ 
Radiation (within 4 months) † 
  No 
  Yes 
Total Radiation Dose 
Radiation EQD2T 
 
42  (17.0) 
204  (82.9) 
68.1 (4.07) 
58.6 (1.74) 
 
0 (0) 
 
105 (42.6) 
222 (90.2) 
 
MyCJ 
 
None 
MAASTRO 
* Percent includes missing values.   
† Delivered within four months of original treatment initiation 
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Supplementary Materials for “Individualized Outcome 
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Section 1: Equations for the Larynx Cancer Outcome Calculators 
In the following report, we describe the models used in each of the four evaluated calculators. We present the 
versions of the four calculators that were available from the respective websites or other sources on 1 November 2016. 
Previous description of the model structures for the Leiden, LifeMath, and MyCancerJourney calculators can be found 
in a similar investigation for oral cavity cancer conducted by Prince et al.
1 
 
Leiden 
The Leiden calculator is based on a Cox proportional hazards regression model. Publications by Datema et al.
 
provide the model structure and parameter estimates but not the baseline survival function.
2,3 
The equations for the 
calculator were derived from a study of 1371 Dutch head and neck cancer patients, of which 638 had larynx cancers. 
The url of the website is https://www.msbi.nl/SV/Chart.aspx?model=Leiden+HNSCC. The baseline 5-year survival was 
obtained through trial and error, i.e. we obtained 5-year survival predictions for a number of patients using the website, 
and then applied the published parameters to solve for the 5-year baseline survival probability. 
 
The form of the model is the following for the i
th
 patient: the hazard (rate) of death at time t is 
λi(t) = λ0(t) exp(βage · agei + βgender · genderi + βcomorbidity · comorbidityi+ 
βT · Ti + βN · Ni  + βM · Mi + βprior · priori + βlocation · locationi) 
where  λ0(t) is the baseline hazard rate at time t. 
There are 8 covariates in this model, and all of them are categorical except for age. Rather than using subject 
age directly, this model determines which of several intervals the true age falls into and then assigns a value for the age 
variable (roughly the midpoint of the age interval) accordingly. In particular, ages 40 or less are assigned a value of 32 
years. Ages 41-50, 51-60, 61-70, 71-80, and greater than 80 are assigned values of 47, 56, 66, 75, and 85 respectively. 
Then, the transformed version of age (with possible values of 32, 47, 56, 66, 75, and 85) is treated as a continuous 
variable in the model. The Comorbidity (ACE27) variable used in this model was adjusted to exclude the contribution 
of prior tumors. λ0(t) is the baseline hazard rate at time t, defined for a 32-year-old male patient whose tumor location 
is lip, with stage T1N0M0 and comorbidity ACE27 score of none, without prior tumors. eTable 1 summarizes the 
covariates from the model above, how they are coded, and the corresponding β coefficients. 
 
eTable 1: Parameter Values in Leiden  
Calculator Cox proportional hazards model 
Covariate Code β 
Age† Continuous 0.04 
Gender Male Reference, 0 
 Female -0.08 
ACE 27* none Reference, 0 
 mild 0.06 
 moderate 0.34 
 severe 0.79 
T T1 Reference, 0 
 T2 0.25 
 T3 0.42 
 T4 0.67 
N N0 Reference, 0 
 N1 0.37 
 N2 0.61 
 N3 0.90 
M M0 Reference, 0 
 M1 1.85 
Prior Tumors No Reference, 0 
 Yes 0.50 
 Lip Reference, 0 
 Hypopharynx 0.62 
 Oral Cavity 0.41 
Location Oropharynx 0.47 
 Glottic larynx 0.04 
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 Supraglottic larynx 0.27 
 Nasopharynx 0.18 
* ACE27 comorbidities excluding contribution for prior tumors 
† Age transformed using the “midpoint” rules previously described 
 
Based on the model for the hazard rates, the 5-year survival probabilities are calculated using the formula S(5) 
= S0(5)
exp(Xβ)
 where exp(Xβ) corresponds to the exponential term in the hazard rate equation above. The baseline 5-year 
survival is defined (in the online calculator) as the 5-year survival probability for a 32-year-old male patient whose tumor 
location is lip, with stage T1N0M0 and comorbidity ACE27 score of none, without prior tumors. The calculated value 
of the 5-year baseline survival is S0(5) = 0.9268.  
 
LifeMath 
The LifeMath calculator does not use a Cox proportional hazard model.
4
 The predicted 5-year survival is based 
on a mechanistic model (SNAP) that assesses the influence of primary tumor and nodes separately. The equations for 
the calculator were developed from a study of 50,145 head and neck cancer patients from the SEER database. The 
website http://www.lifemath.net/cancer/headneck/outcome/  provides source code in JavaScript, thereby providing all 
parameters and a table of conversion factors for this calculator. Similar LifeMath calculators are available for breast 
cancer, melanoma, renal cell cancer, and colon cancer. 
The components of the model can be computed using the formulas below: for each patient, let Lprimary and 
Lnodes denote the contributions to the calculated head and neck cancer specific survival from the primary tumor and the 
nodes respectively. LHNSC10 is the estimated 10-year cancer specific survival, which is adjusted to 5-year overall 
survival estimate using a table of age and gender specific factors derived from the SEER data. Lprimary, Lnodes, and 
LHNSC10 are defined as follows: 
Lprimary = 1 − exp(−Q · jprimary · (10 · diameter)
Z · g)  
Lnodes  = 1 − exp(−nodes · R · g) 
LHNSC10 = Lprimary + Lnodes − Lprimary · Lnodes 
 
These equations depend on several constants, which take values (truncated at 4 decimal places) of:  
Q = 0.1059 
jprimary = 0.6944 
Z = 0.5721 
R = 0.1365 
In the equation, “diameter” is the primary tumor size at the greatest dimension and “nodes” is the number of 
nodes. When the number of nodes is unknown, the program sets number of nodes to be 0 and changes jprimary to be 
1.The g term in the formulas above represents the effects from all other covariates, including age, race, gender, N stage, 
extension and ECS (extra capsular spread). The g term for patient i was calculated in the following way: 
gi = exp (βage · agei + βrace · racei + βsite · sitei + βN · Ni + βECS · ECSi). 
The covariates, how they are coded and the coefficients (specific to Larynx cancer) are shown in eTable 2. 
 
eTable 2: Lifemath SNAP Model Parameters 
(parameters for g expression)* 
Covariate Code β 
Age 36 - 45 -0.332 
 46 - 55 -0.183 
 56 - 65 -0.040 
 66 - 75 0.172 
 76 - 95 0.393 
 else 0 
Race Black 0.275 
 White -0.095 
 Other -0.118 
 Unknown 0 
Site Oral Cavity 0.054 
 Hypopharynx 0.409 
 Larynx 0.051 
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 Oropharynx -0.135 
 Nasopharynx -0.002 
N Stage N0/Unknown 0 
 N1 0.175 
 N2a 0.216 
 N2b 0.271 
 N2c 0.337 
 N3 0.507 
ECS Absent/Unknown 0 
 Present 0.378 
   *Truncated at three decimal places 
 
For other cancer sites, this model contains additional interaction terms, but there are no additional interaction terms for 
the Larynx cancer subsite. For more details about this model in other subsites, see Prince et al.
1 
 
MyCancerJourney 
The MyCancerJourney (MyCJ) calculator https://staging.mycancerjourney.com/  is based on a Cox proportional 
hazards regression model, and it is more complicated than the other Cox models considered because it includes many 
interactions terms. No calculator information is available from the website, and it is not described by a peer reviewed 
publication, and there is no evidence that the model has been validated in external data. The equations for the calculator 
were developed from a combination of two datasets. One consisted of 11,791 patients with any cancer treated at the 
Siteman Cancer Center/Barnes-Jewish hospital and the other included over 2 million cancer patients in the SEER 
database.  
All the parameters and baseline survival estimates that are relevant for larynx cancer patients were obtained by 
trial and error. The trial and error process is the following: default options from the website as baseline were used (which 
will be described below), and each variable was separately changed while holding other variables constant. The 
parameter coefficient for the variable that best corresponds to the results from the website was then determined. All the 
parameter estimates as well as interaction terms were obtained through repeating the above procedure.  
The hazard rate at time t is computed as follows (for larynx cancer patients only): 
 
λi(t) = λ0(t) exp(βage · agei + βgender · genderi + βrace · racei + βcomorbidity · comorbidityi   (Main Effects) 
+ βhistology · histologyi + βstage · stagei + βgrade · gradei      (Main Effects) 
+ βsurgery · surgeryi + βchemo · chemoi + βradiation · radiationi     (Main Effects) 
+ βage-gender · agei · genderi + βage-race · agei · racei + βage-stage · agei · stagei    (Interactions) 
+ βage-comorbidity · agei · comorbidityi + βsurgery-chemo · surgeryi · chemoi   (Interactions) 
+ βgender-comorbidity · genderi · comorbidityi + βrace-comorbidity · racei · comorbidityi   (Interactions) 
+ βchemo-comorbidity · chemoi · comorbidityi + βhistology-comorbidity · histologyi · comorbidityi   (Interactions) 
+ βhistology-grade · histologyi · gradei + βradiation-stage · radiationi · stagei)    (Interactions) 
 
where λ0(t)  is the annual rate of death at time t for a 60- to 64-year-old white male patient with squamous cell 
histology with in situ stage, grade 1 tumor, without comorbidity or any treatment, and with Larynx cancer subsite. The 
hazard rate is determined by 11 main effects and several interaction terms. Their coding as well as the estimated βs for 
the main effect and interaction terms are shown in eTables 3 and 4 respectively. Note that the “in situ” and “local” 
stages and “G1” and “G9” (Unknown) grades have the same hazard ratio. Therefore, both are marked as reference. 
 
eTable 3: Main Effect Parameter Values in  
MyCancerJourney Cox proportional hazards model 
Covariate Code β 
Age <35 -0.86 
 35 - 39 -0.69 
 40 - 44 -0.69 
 45 - 49 -0.32 
 50 - 54 -0.39 
 55 - 59 -0.23 
 60 - 64 Reference, 0 
 65 - 69 0.06 
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 70 - 74 0.33 
 75 - 79 0.59 
 80 - 84 0.34 
 >84 0.51 
Gender Male Reference, 0 
 Female -0.39 
Race White/Other Reference, 0 
 Black -0.25 
Comorbidity None Reference, 0 
 Mild 0.23 
 Moderate 0.49 
 Severe 1.14 
Histology Squamous Cell Reference, 0 
 Other -0.13 
Stage (SEER) in situ/Local Reference, 0 
 Regional 0.95 
 Distant 1.65 
Grade G1/G9 (Unknown) Reference, 0 
 G2 0.17 
 G3 0.33 
 G4 -0.19 
Surgery No Reference, 0 
 Yes -1.14 
Chemotherapy No Reference, 0 
 Yes -0.05 
Radiation No Reference, 0 
 Yes -0.62 
eTable 4: Interaction Parameter Values in  
MyCancerJourney Cox proportional hazards model 
Covariate Interaction  β 
Age - Gender Interaction 
  Age in 40-44 and Gender = Female 
  Age >84 and Gender = Female 
  Else
a 
 
0.86 
0.80 
0 
Age - Race 
  Age in 40-44 and Race = Black                                 
  Age in 50-54 and Race = Black 
  Age in 55-59 and Race = Black 
  Age in 65-69 and Race = Black 
  Else 
 
1.02 
0.66 
0.57 
0.61 
0 
Age - Stage 
  Age in 75-79 and Stage = Regional 
  Age in 80-84 and Stage = Distant  
  Else 
 
-0.46 
-1.46 
0 
Age - Comorbidity 
  Age in 75-79 and Comorbidity = Severe 
  Age >84 and Comorbidity = Severe 
  Else  
 
-0.73 
-1.01 
0 
Treatment - Treatment 
  Surgery = Yes and Chemo = Yes  
  Else 
 
0.76 
0 
Gender - Comorbidity 
  Gender = Female and Comorbidity = Mild 
  Else  
 
0.31 
0 
Race - Comorbidity 
  Race = Black and Comorbidity = Severe 
  Else  
 
-0.46 
0 
Treatment and Comorbidity  
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  Chemo = Yes and Comorbidity = Severe 
  Else  
-0.37 
0 
Histology - Comorbidity 
  Histology = Other and Comorbidity = Severe  
  Else 
 
1.18 
0 
Histology - Grade 
  Histology = Other and Grade = G2  
  Else 
 
-1.11 
0 
Treatment - Stage 
  Radiation = Yes and Stage = Distant 
  Else  
 
-0.47 
0 
a Interaction terms are nonzero only for certain covariate combinations 
  
The baseline 5-year survival is defined as the 5-year survival probability for a 60- to 64-year-old white male 
patient with squamous cell histology with in situ stage, grade 1 tumor, without comorbidity or any treatment, and with 
Larynx cancer subsite. The value is S0(5) = 0.481. The 5-year survival is then estimated using the equation S(5) = 
S0(5)
exp(Xβ)
 where exp(Xβ) is the exponential term in the hazard rate expression above. 
We note that the large number of interaction terms in the MyCJ model does lead to some strange features and 
may result from overfitting. For black patients, for example, there is a decrease in the survival only for very specific 
age ranges 40-44 and 50-59 and 65-69, but not for other age ranges. However, there is no comparable noticeable 
change in survival for specific age ranges for white patients.  
 
Maastro 
The Maastro calculator ( http://www.predictcancer.org/Main.php?page=LarynxFollowUpModel) is based on a 
Cox proportional hazards model. Egelmeer et al. (2011) provides the structure of the model and a set of parameter 
estimates.
5
 However, the predicted survivals from the online calculator did not match the parameter estimates provided 
in the paper, so we believe the model used in the online calculator as of November 1
st
 2016 is an updated version of the 
model published in 2011.
5
 According to information available on the website, the model was developed using a dataset 
of 994 patients with squamous cell laryngeal carcinoma that were treated at the Maastro clinic in the Netherlands from 
January 1977 to December 2008. This model was validated using data from 895 patients from four different cohorts 
from Leuven (Belgium), Amsterdam (VU and NKI/ALV Hospital), and Manchester (UK). This calculator was intended 
to be used only for larynx cancer patients that were cancer stage I-IV, were treated with high dose radiotherapy alone 
(so no surgery or chemotherapy), and had no distant metastases at the time of diagnosis. It is noted in the main text that 
we ignored the eligibility criteria by applying the Maastro model to all patients, including patients who received other 
treatments in addition to radiation. Therefore, we apply this model to some patients who do not meet the eligibility 
requirements for the model. When we applied the Maastro model strictly to the subset of our patient population that 
received radiation only (and no induction chemotherapy) as part of the initial treatment plan (N=55), we obtain the 
results presented in Section 7 of this document. 
Model parameters and the baseline survival probability were estimated by trial and error using the online 
calculator. Hazard ratios were estimated by separately changing the value of each variable, holding the other variables 
constant. The baseline survival probability was determined using the hazard ratio estimates we obtained and the online 
5-year survival predictions for a large group of subjects. The form of the model is the following for the ith patient: the 
hazard of death at time t is 
λi(t) = λ0(t) exp(βage · agei + βgender · genderi + βT · Tstagei + βN · Nstagei+ 
βlocation · locationi + βhemoglobin · hemoglobini + βEQD2T · EQD2Ti) 
 
eTable 5: Parameter Values in Maastro Calculator  
Cox proportional hazards model 
Covariate Hazard Ratio beta=ln(HR) 
Age 1.05 0.045 
Gender   
Female (ref) 1 0 
Male 2.38 0.865 
T Stage   
T1 (ref) 1 0 
T2 1.13 0.121 
T3 1.96 0.675 
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T4 3.60 1.279 
N Stage   
N0 (ref) 1 0 
N+ 1.44 0.364 
Location   
Glottic (ref) 1 0 
Non-Glottic 1.31 0.266 
Hemoglobin Level (in mmol/L) 0.73 -0.321 
EQD2T 0.99 -0.004 
 
The estimated baseline survival probability, S0(5) = 0.6545 represents the 5-year survival probability for a female 
subject with T1N0, glottic cancer with value 0 for all continuous variables in the model (including age). This survival 
probability, therefore, does not have much practical meaning. The 5-year survival is then estimated using the equation 
S(5) = S0(5)
exp(Xβ)
 where exp(Xβ) is the exponential term in the hazard rate expression above. 
 
Section 2: Treatment of Missing Data 
Tumor diameter, hemoglobin, and EQD2T were not available for some of the patients. We developed a set of 
rules for determining reasonable values to assign each patient with missing values. For patients missing tumor 
diameter, diameters of 1cm, 2cm, 3cm, and 4cm were assigned for T1, T2, T3, and T4 patients respectively. This was 
consistent with the pattern of diameters seen for subjects with both diameter and T stage observed. We also had a few 
(18%) subjects missing values for hemoglobin. We used single imputation to fill in the missing values of hemoglobin 
based on a regression model of hemoglobin that included gender, comorbidities, age, main tumor site, CA stage, SEER 
stage, and initial treatment as covariates. 
Missing values of EQD2T were handled using as much of the available information as possible. EQD2T is a 
function of total radiation dose, dose per fraction, and treatment time. EQD2T can only be measured in subjects that 
received radiation. For our primary analyses, we calculate EQD2T as if all subjects received radiation. We note that 
analyses restricted to subjects that actually received radiation produced similar results. For subjects missing total 
radiation dose, dose per fraction, and treatment time, a total dose of 63 was assigned to T1N0Glottic patients and a total 
dose of 70 was assigned for all others. Dose per fraction was assigned to be 2Gy and then treatment time was assigned 
a reasonable value based on the relationship between duration of treatment and (total dose/dose per fraction) in the 
observed data. For subjects with observed total dose and either dose per fraction or duration of treatment missing (but 
not both), we set the missing variable to take a reasonable value based on the observed data. For subjects with total 
dose observed and missing values for dose per fraction and duration, we assign dose per fraction to 2Gy and set 
duration to a reasonable value based on the observed data. It is worth noting that the coefficient in the Maastro model 
corresponding to EQD2T is near zero, so the value of EQD2T (within a reasonable range) will have little impact on the 
final 5-year survival prediction. Therefore, we do not expect the missing (and subsequently imputed) EQD2T values to 
have much impact.  
Utilization of chemotherapy after definitive treatment was not available for some subjects, and we therefore 
developed a set of rules to incorporate adjuvant chemotherapy. A subject receiving no induction chemotherapy and 
surgery as his/her initial treatment plan was listed as having had adjuvant chemotherapy if the subject had extracapsular 
spread and/or positive margins. 
 
Section 3: Reconstructed Model Performance 
It was not necessary to characterize the model (determine the exact model form and all parameter values) for 
the various calculators, but it was very convenient. To check the accuracy of the reconstructed calculators we compared 
the results of the online calculator (when available) with our program. Thirty patients with larynx cancer were 
randomly drawn from the University of Michigan dataset, and their information was used to predict 5-year survival 
using both the web calculator and our reconstructed models. We did not include the LifeMath model as the exact form 
of the model and all associated parameter values were available, allowing for exact duplication of the online calculator. 
eTable 6 shows the predicted survival probabilities from the website and our reconstructed calculator for the 
Maastro, LifeMath, and Leiden calculators. The results show that the Leiden calculator has some minor prediction 
errors for a small number of patients, the maximum absolute value of prediction error (the maximum error in the 
“Difference” column) between the online prediction and a rounded version of the reconstructed prediction is 1% in 5-
year survival probability. The reason for this difference is likely due to rounding error as the publication only provides 
the coefficient values to 2 significant digits. Similarly, the maximum absolute value of prediction error for the Maastro 
calculator is 1% in 5-year survival probability. A greater number of patients have an absolute difference equal to 1 for 
the Maastro calculator than the Leiden calculator, which is likely due to issues of rounding or truncation of the 
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predictions for the online calculator. MyCancerJourney calculator also has minor prediction errors for larynx cancer 
patients, the maximum absolute value of prediction error is 0.3%.
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eTable 6: Comparison of 5-Year Survival Predictions from the Reconstructed 
Models and Web Calculators 
 
 
Maastro
a 
Leiden MyCJ 
Web Recon Difference Web Recon Difference Web Recon Difference 
10 9 1 26 25 1 9.1 9.2 -0.1 
67 66 1 77 77 0 50 50.3 -0.3 
47 47 0 66 66 0 16.7 16.8 -0.1 
10 10 0 53 53 0 21.6 21.8 -0.2 
29 30 -1 38 38 0 36 36.2 -0.2 
61 61 0 62 63 -1 40.2 40.4 -0.2 
12 12 0 24 23 1 0.8 0.8 0.0 
35 35 0 43 43 0 32.8 32.8 0.0 
20 20 0 46 46 0 51.8 51.9 -0.1 
34 35 -1 54 54 0 58.8 59.0 -0.2 
<5 2 NA 49 49 0 59.2 59.4 -0.2 
<5 1 NA 27 27 0 34.4 34.6 -0.2 
67 67 0 75 75 0 72 71.9 0.1 
56 56 0 76 76 0 67.6 67.6 0.0 
<5 3 NA 47 47 0 28 28.1 -0.1 
35 36 -1 54 54 0 40.6 40.7 -0.1 
35 35 0 42 42 0 21.1 21.2 -0.1 
<5 2 NA 21 21 0 15.5 15.6 -0.1 
23 23 0 50 50 0 38.8 38.9 -0.1 
72 72 0 77 77 0 77 77.0 0.0 
16 17 -1 22 22 0 40.6 40.6 0.0 
23 24 -1 49 49 0 26.9 27.0 -0.1 
9 10 -1 50 50 0 58.4 58.5 -0.1 
<5 5 NA 31 30 1 0.5 0.5 0.0 
19 19 0 49 49 0 41.3 41.4 -0.1 
42 42 0 47 46 1 28.3 28.6 -0.3 
50 51 -1 52 52 0 48.7 48.8 -0.1 
25 25 0 65 65 0 40.8 40.9 -0.1 
91 91 0 91 91 0 83.5 83.5 0.0 
<5 1 NA 46 46 0 29.3 29.3 0.0 
a The values in the table correspond to the 5-year survival probability predictions. The “Web” column lists the (rounded) predicted 5-
year survival probability from the corresponding website and “Recon” column lists the 5-year survival probability predicted using the 
reconstructed models. The differences between the online value and the rounded version of the reconstructed value are also included. All 
the values in this table have unit % and represent probabilities. 
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Section 4: Summary of Models and Pairwise Agreement 
eTable 7 summarizes the variables included in each of the four larynx cancer models. We also take a look 
at the pairwise agreement between the calculators. For each subject in our dataset, we obtain a calculator prediction 
of 5-year survival using each of the calculators. eTable 8 shows the proportion of predictions that are within 10% of 
one another. 
 
eTable 7: Summary of Input Variables for Larynx Cancer Calculator 
 
 Calculator MAASTRO Lifemath Leiden MyCJ 
Demographic Age Y Y Y Y 
 Sex Y  Y Y 
 Race  Y  Y 
 Comorbidity   Y Y 
 Prior Tumors   Y  
Site Laryngeal Subsites Y  Y  
 Other HNC  Y Y Y 
Staging Histology    Y 
 Grade    Y 
 Tumor Diameter  Y   
 T Y  Y  
 N Y Y Y  
 Number of Positive Nodes  Y   
 M   Y  
 SEER Stage    Y 
Other Hemoglobin Y    
 Extracapsular Spread  Y   
 EQD2T Y    
 Treatment    Y 
 
 
eTable 8: Proportion of Survival Predictions within 10% for Pairs of Calculatorsa 
 
 LifeMath Leiden MyCJ Mean
b 
Maastro 18.2% 23.1% 30.4% 32.1% 
LifeMath  70.3% 39.4% 55.2% 
Leiden   39.8% 58.9% 
MyCJ    60.9% 
a Eg. For a predicted survival of 0.5, this is between 0.4 and 0.6. 
b The Mean is the arithmetic average of the LifeMath, Leiden, Maastro, and MyCJ 5-year survival probability predictions
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Section 5: Cox Regressions using Calculator Predictions 
We are interested in identifying subjects in our cohort that demonstrate improved survival compared to the 
calculator predictions. We define S to be the mean of the estimated 5-year survivals for the Leiden and LifeMath 
calculators. e Table 9 shows Cox regressions of Overall Survival (censored at 70 months). Each row corresponds to a 
separate Cox regression adjusting for −log(−log(S)) and the corresponding covariate. The results suggest that, even 
adjusting for the predicted survivals, we have lower rates of death in subjects that are female compared to male and 
subjects that receive “No Induction and Surgery” or “Induction Chemo” compared to “No Induction and 
Chemoradiation” as their initial treatment plan. 
 
eTable 9: Cox Model Regression Results: Importance of Each Factor 
After Adjusting for the Leiden and LifeMath Predictions 
 
Covariate Covariate HR (95% CI)
a 
Covariate P-value −log(−log(S)) HR (95% CI) 
T Stage  0.676  
  T1 (ref) 1   
  T2 1.35 (0.61, 2.97)  0.25 (0.14, 0.43) 
  T3 0.94 (0.44, 2.04)   
  T4 0.88 (0.39, 1.95)   
Gender  0.031  
  Female (ref) 1   
  Male 2.03 (1.00, 4.11)  0.26 (0.16, 0.44) 
Comorbidities  0.734  
  None (ref) 1   
  Mild 1.05 (0.49, 2.26)  0.29 (0.17, 0.48) 
  Moderate 1.33 (0.59, 2.97)   
  Severe 1.48 (0.58, 3.73)   
N Stage  0.469  
  N0 (ref) 1   
  N1 1.10 (0.52, 2.33)  0.22 (0.12, 0.41) 
  N2/N3 0.71 (0.38, 1.34)   
Initial Treatment Plan  0.024  
  No Induction, Chemoradiation 1  0.24 (0.14, 0.41) 
  No Induction, Radiation Only 0.97 (0.49, 1.88)   
  No Induction, Surgery 0.43 (0.21, 0.90)   
  Induction Chemo 0.46 (0.24, 0.88)   
Age  0.448  
  10 Years Increase (ref) 1.10 (0.85, 1.44)  0.30 (0.17, 0.53) 
Race  0.347  
  White (ref) 1   
  Black 1.70 (0.61, 4.68)  0.28 (0.17, 0.46) 
  Other 0.39 (0.05, 2.88)   
SEER Stage  0.982  
  Local (ref) 1   
  Regional 0.94 (0.49, 1.78)  0.26 (0.15, 0.47) 
  Distant 0.96 (0.47, 1.97)   
CA Stage  0.547  
  I (ref) 1   
  II 1.86 (0.74, 4.71)  0.24 (0.13, 0.45) 
  III 1.22 (0.51, 2.90)   
  IV 1.06 (0.47, 2.38)   
Subsite    
  Glottic (ref) 1   
  Supraglottic 0.89  (0.52, 1.52) 0.671 0.26  (0.15, 0.44) 
Grade  0.732  
  Well Differentiated (ref) 1   
  Moderately Differentiated 1.33 (0.50, 3.54)  0.29  (0.17, 0.49) 
  Poorly 1.66 (0.58, 4.74)   
  Unknown 1.58 (0.56, 4.43)   
a If the covariate is significantly associated with overall survival even after adjusting for the 5-year survival predictions, this suggests that the 
calculator predictions are not fully capturing the covariate effect on the outcome. 
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Section 6: Creating the Calibration Plots 
In order to assess how well each of the calculator’s predictions corresponded to the observed data, we 
construct calibration plots. We use two different methods. 
Method 1: For each calculator, we separate subjects into 5 groups based on quintiles of the calculator’s 
predicted 5-year survival probabilities. Within each group, we estimate the 5-year survival probability from the 
observed data for subjects in that group. We plot the average calculator predictions for each of the groups against the 
estimated survival probabilities from the observed data. Points closer to the y=x line correspond to better calibration. 
Method 2: Method 1 only breaks the subjects into 5 groups for each calculator, which results in only 5 points 
from which to evaluate calibration. Together, these points provide a rough idea of the relationship between the 
calculator predictions and the Kaplan-Meier predictions. Alternatively, we might identify a smoother and more refined 
version of the relationship between the calculator and Kaplan-Meier 5-year survival predictions by breaking the 
predictions into many overlapping groups rather than 5 non-overlapping groups. The overlapping groups are 
determined based on the subjects with calculator-predicted 5-year survival probabilities within a moving window of 
0.25. Within each group, we plot the average predicted 5-year survival probability from the calculator against the 
Kaplan-Meier-predicted 5-year survival probability for the group. This is a form of a kernel smoother and results in a 
smoothed version of the calibration plot. We use this approach to identify patient characteristics in our cohort that may 
be associated with improved survival over the calculator predictions. 
 
Section 7: Maastro Predictions Restricted to Cohort Receiving Radiation 
The Maastro calculator was created and validated for subjects receiving radiation only (no surgery or 
chemotherapy), but our primary analysis applies the Maastro calculator to some subjects that did not receive radiation 
and patients receiving radiation in addition to other treatments. Therefore, we are applying the Maastro calculator to a 
population it was not designed for, which does not present a “level playing field” for the various calculators. Therefore, 
we are interested in comparing the performance of the calculators on the subset of patients receiving radiation only 
(and no induction chemo) as the initial treatment plan (N=55). 
eTable 10 shows the proportion of predictions that are within 10% of one another. The Maastro calculator is 
more similar to the other calculators when applied to the “radiation only” subset of the population. eFigure 1 shows the 
comparison of the predicted survivals across calculators. Maastro is more strongly correlated to the other calculators, 
but it still tends to underestimate the survival probabilities relative to the other calculators. eFigure 2 shows calibration 
curves for each one of the calculators using only the data from the radiation only subset of the data. Similar to the 
analysis of the entire sample, the Maastro calculator underestimates the survival probabilities observed in our data. The 
Leiden and LifeMath calculators appear to have better calibration than the Maastro calculator for the radiation only 
subset. eFigure 3 displays the resulting ROC curves. Here, the results differ from the results obtained from analysis of 
the entire study sample. Using the radiation only subset of the data, we see that the Maastro calculator has substantially 
improved AUC and C Index values. 
 
eTable 10: Proportion of Survival Predictions within 10% for Pairs of Calculators, 
Restricted to subjects receiving radiation onlya 
 
 LifeMath Leiden MyCJ Mean 
Maastro 34.5 % 29.0% 38.1% 50.9% 
LifeMath  72.7% 45.4% 76.3% 
Leiden   29.0% 61.8% 
MyCJ    69.0% 
a Eg. For a predicted survival of 0.5, this is between 0.4 and 0.6. 
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eFigure 1: Comparing Predicted Survivals Across Calculators using Subjects 
Receiving Radiation Only 
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eFigure 2: Calibration Curves using Subjects Receiving Radiation Onlya 
 
a Calibration curves estimated using smoothing method as described in Section 6 of the Supplementary Materials 
 
eFigure 3: 5-year ROC Curves using Subjects Receiving Radiation Onlya 
 
a The ROC curve illustrates the ability of each calculator to discriminate subjects with higher and lower 5-year 
survival. The AUC is the area under the ROC survival curve, with values closer to 1 indicated greater predictive 
ability. The C-Index (Concordance Index) is a measure of how well the predicted survival probabilities rank subjects 
with respect to higher and lower observed risk.
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